|Awarded On||February 18, 2015|
|Title||EGFR Arginine Methylations: Biomarkers for Cetuximab Resistance in colon cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Mien-Chie Hung|
Epidermal growth factor receptor (EGFR) is a key enzyme that controls cell proliferation and growth, and is aberrantly activated in multiple human cancers. The EGFR inhibiting monoclonal antibody cetuximab (Erbitux) has been used to treat colorectal cancer (CRC) patients. Cetuximab alone or in combination with chemotherapy has shown efficacy in CRC treatment; however, significant numbers of patients exhibit resistance to cetuximab and the underlying mechanisms are not completely understood. Thus, it is extremely important to identify the subpopulation of EGFR-overexpressing CRC patients that will respond to treatment with cetuximab. In addition, understanding the mechanism of resistance for ...